Short Interest in Pluri Inc. (NASDAQ:PLUR) Increases By 176.6%

Pluri Inc. (NASDAQ:PLUR) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 35,400 shares, an increase of 176.6% from the March 31st total of 12,800 shares. Based on an average daily trading volume, of 29,700 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.9% of the company’s shares are short sold.

Pluri Trading Up 9.3 %

NASDAQ PLUR traded up $0.46 on Friday, hitting $5.36. 6,889 shares of the stock were exchanged, compared to its average volume of 55,723. Pluri has a 52-week low of $3.45 and a 52-week high of $8.56. The company has a debt-to-equity ratio of 3.69, a current ratio of 7.12 and a quick ratio of 7.12. The company has a market capitalization of $27.75 million, a price-to-earnings ratio of -1.15 and a beta of 1.45. The company’s 50-day moving average price is $6.40 and its two-hundred day moving average price is $5.36.

Pluri (NASDAQ:PLUR) last announced its quarterly earnings data on Monday, February 12th. The company reported ($0.96) EPS for the quarter. Pluri had a negative return on equity of 177.94% and a negative net margin of 6,708.40%. The business had revenue of $0.11 million for the quarter.

Institutional Trading of Pluri

A hedge fund recently raised its stake in Pluri stock. Values First Advisors Inc. raised its stake in shares of Pluri Inc. (NASDAQ:PLUR) by 168.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 135,547 shares of the company’s stock after buying an additional 85,037 shares during the period. Values First Advisors Inc. owned about 0.33% of Pluri worth $81,000 as of its most recent SEC filing. Institutional investors and hedge funds own 16.59% of the company’s stock.

About Pluri

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.